Tier 1 newswiremarketwatch.com
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
In recent news, Lilly's addition of a new amylin drug to Zepbound demonstrates potential for significant weight loss—up to 23%—while also introducing more side effects. This development is crucial as it underscores the ongoing evolution in pharmaceuticals aimed at combating obesity and diabetes, echoing trends seen with GLP-1 receptor agonists. As these drugs emerge, their market reception could influence investor sentiment and align with broader economic discussions around health spending, which could have indirect impacts on currency valuations.